To evaluate autophagy inhibition in patient-derived material, we next measured autophagy inhibition following drug treatment in stem cell-enriched (CD34+) cells, isolated from individuals with chronic phase CML. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.